DUBLIN, Calif., July 11 /PRNewswire/ -- Microchip Biotechnologies, Inc. is pleased to announce that it has secured key patent rights from Pathwork Diagnostics for sample injection structures in microfluidic separations. The pending patent relates to improved sample injection structures and methods for defining accurate volumes of material for microfluidic separations. Financial terms of the transaction were not released.
“The addition of this intellectual property to our patent portfolio builds upon our strong patent position in microfluidic devices for life science, applied sciences, and diagnostic products,” said Dr. Stevan Jovanovich, President and CEO of MBI. “Microfluidic devices will play a critical role in next-generation instrumentation to deliver fully automated, cost effective solutions for laboratory and field based applications.”
The acquired pending patent was held previously by Predicant Biosciences, which in a June 2006 merger became Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology.
About Pathwork Diagnostics
Pathwork Diagnostics, based in Sunnyvale, California, develops and delivers genomics-based diagnostics that advance cancer care. The company solves unmet needs in oncology by combining microarray technology with proprietary informatics to provide clinically actionable information in a robust and reproducible manner. The company’s first test -- the Pathwork(TM) Tissue of Origin Test -- is under FDA review and is expected to aid in the diagnosis of patients with uncertain primary cancers, in which a tumor’s origin cannot be readily identified. This approach could potentially enable oncologists to begin standard-of-care, tissue-directed management more promptly for patients. More information is available at http://www.pathworkdx.com.
About Microchip Biotechnologies
Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solution are based on MBI’s proprietary “NanoBioProcessorTM platform and associated “Microscale-on-Chip-Valves” (MOV(TM)). More details can be found on the Company’s website: http://www.microchipbiotech.com.
Microchip Biotechnologies, Inc.
CONTACT: Barney Saunders, Ph.D, Chief Commercial Officer of MicrochipBiotechnologies, Inc., +1-925-558-2028,barney.saunders@microchipbiotech.com
